Over-the-Counter Naloxone Nasal Spray Expands Opioid

Medically reviewed | Published: | Evidence level: 1A
The FDA has approved another nonprescription intranasal naloxone product, Rextovy, for emergency treatment of known or suspected opioid overdose. The move expands a public health strategy aimed at making opioid overdose reversal medication easier to obtain before an emergency happens.
📅 Published:
Reviewed by iMedic Medical Editorial Team
📄 Public Health

Quick Facts

FDA Status
OTC approval
Drug Class
Opioid antagonist
Route
Nasal spray

What Does OTC Naloxone Approval Mean for Overdose Prevention?

Quick answer: Over-the-counter approval means naloxone can be sold without a prescription, making it easier for families, bystanders, schools, and community groups to keep it available.

Naloxone is an opioid antagonist that can rapidly reverse life-threatening respiratory depression caused by opioids such as heroin, oxycodone, morphine, and fentanyl. By approving another nonprescription nasal spray, the FDA is increasing the number of products that can be stocked in pharmacies, retail stores, workplaces, campuses, and homes without requiring a clinician visit first.

This matters because opioid overdoses are time-sensitive medical emergencies. Naloxone can restore breathing, but emergency medical care is still required because some opioids last longer than naloxone and symptoms can return. Public health agencies including the CDC and FDA continue to recommend calling emergency services immediately after giving naloxone.

How Does Naloxone Nasal Spray Work During an Opioid Overdose?

Quick answer: Naloxone temporarily displaces opioids from receptors in the brain and can help restore breathing within minutes.

Opioids can suppress the brainstem signals that control breathing. Naloxone binds to opioid receptors with high affinity, blocking or displacing opioid molecules and reversing sedation and respiratory depression. The nasal spray format is designed for bystander use because it does not require needles, assembly, or medical training.

Signs of possible opioid overdose include very slow or stopped breathing, blue or gray lips or fingertips, inability to wake up, limpness, gurgling sounds, or pinpoint pupils. If a person does not respond after the first dose, product labeling commonly advises repeat dosing while waiting for emergency responders, especially when potent synthetic opioids may be involved.

Who Should Consider Keeping Naloxone Available?

Quick answer: Naloxone is especially important for people who use opioids, their households, first responders, and any setting where overdose may occur.

Medical and public health groups encourage wider naloxone availability because many overdoses happen in the presence of another person. People at higher risk include those taking high-dose prescription opioids, people using opioids with benzodiazepines or alcohol, individuals with opioid use disorder, and people returning to use after a period of abstinence.

Naloxone is not a substitute for addiction treatment, pain care, or emergency response. Its value is immediate survival: it can create a critical window for rescue breathing, emergency services, and linkage to treatment with evidence-based medications such as buprenorphine or methadone when opioid use disorder is present.

Frequently Asked Questions

Naloxone has no meaningful effect if opioids are not present, so public health agencies advise giving it when opioid overdose is suspected rather than delaying treatment.

Yes. Naloxone can wear off before the opioid does, and breathing problems may return. Emergency medical evaluation is recommended after every suspected overdose.

No. Naloxone reverses an overdose emergency, while opioid use disorder treatment usually requires ongoing care, counseling support, and medications such as buprenorphine or methadone when appropriate.

References

  1. U.S. Food and Drug Administration. FDA approves first over-the-counter naloxone nasal spray. 2023.
  2. Centers for Disease Control and Prevention. Lifesaving Naloxone.
  3. Medical Xpress. FDA approves another over-the-counter naloxone nasal spray. June 2026.